Europe Patient Monitoring Devices Market

Europe Patient Monitoring Devices Market Analysis

The Europe Patient Monitoring Devices Market size is estimated at USD 1.36 billion in 2025, and is expected to reach USD 3.17 billion by 2030, at a CAGR of 18.42% during the forecast period (2025-2030).

The major factors driving the market growth include the rising burden of chronic diseases due to lifestyle changes and the growing preference for home and remote monitoring. Patients undergoing chemotherapy or radiation therapy may use devices to monitor vital signs and blood counts to manage side effects and treatment response. For instance, according to the data updated by the Santé Publique France in July 2023, an estimated 433 thousand new cancer diagnoses occured in France in 2023. The source also stated that new cancer cases in women are increasing faster, with the median age of diagnosis being 68 years old (compared to 70 years old for men). Also, as per the same source, the top three most prevalent forms of cancer in men were prostate, lung, and colorectal, respectively. Similarly, breast cancer was the most prevalent form of cancer in women, followed by colorectal and lung cancer.

In addition, patients with hypertension, arrhythmias, and heart failure can benefit from devices like blood pressure monitors, electrocardiogram (ECG) monitors, and wearable heart rate monitors to keep track of their heart health. For instance, according to the data released by the British Heart Foundation in September 2024, currently, 7.6 million people are living with a heart or circulatory disease in the United Kingdom. As per the same source, around 80 percent of people with heart and circulatory diseases have at least one other health condition. Thus, the region's high prevalence of heart disease is projected to drive the adoption of patient monitoring devices during the forecast period.

Furthermore, the increasing number of fundings and partnerships by prominent players is projected to drive market growth during the forecast period. For instance, in November 2023, Bertelsmann Investments (BI) invested USD 5.59 million in Doccla, a European provider of virtual hospital platform for telemonitoring. This funding helps Doccla improve its technology, making remote patient monitoring at home more effective and user-friendly. With better resources, Doccla can expand its reach across Europe, making healthcare more accessible, especially for people in remote areas. The investment also supports research and development to innovate and refine their services, leading to better patient outcomes through timely interventions.

Similarly, in September 2024, Nonin Medical, known for its SpO₂ monitoring solutions, collaborated with Corscience, a German specialist in CO₂ monitoring, to jointly promote their patient monitoring technologies. By promoting each other's OEM products, both companies aim to use their unique strengths to meet the rising demands of healthcare providers. Through this partnership, Nonin expands its portfolio to include CO₂ monitoring, and Corscience adds advanced SpO₂ technology to its range. This collaboration leads to integrated solutions, improving patient care, optimizing clinical workflows, and potentially lowering costs for healthcare facilities. Such initiatives by key players are projected to boost the market growth in the Europe.

Therefore, factors such as the rising prevalence of chronic diseases and increasing number of fundings and partnerships by prominent players are projected to drive market growth during the forecast period. However, regulatory challenges and data security concerns may restrain the market growth during the forecast period.

Europe Patient Monitoring Devices Market Trends

The Weight Management and Fitness Monitoring Segment is Expected to Register a Significant Share of the Market Over the Forecast Period

The growth of the weight management and fitness monitoring segment in the European patient monitoring device market is primarily driven by an increasing awareness of the importance of preventive healthcare and the rising prevalence of lifestyle-related diseases such as obesity and diabetes. Additionally, advancements in wearable technology and mobile health applications have empowered individuals to take a more proactive role in monitoring and managing their health, leading to a growing demand for fitness trackers and weight management devices.

The rising prevalence of obesity in the region is projected to drive market growth during the forecast period. For instance, according to the World Obesity Atlas Report published in March 2023, around 14% of girls and 21% of boys are expected to be affected by obesity in Europe by 2035. As per the same source, around 102 million adults are projected to suffer from obesity in Europe by the end of 2025, which is set to increase to 117 million by the end of 2030. Thus, the rising prevalence of obesity in the region will drive market growth during the forecast period.

Furthermore, the growing strategic initiatives by key players, such as acquisitions to expand access to AI-powered weight loss programs, is also projected to drive market growth during the forecast period. For instance, in June 2023, Allurion, a company committed to fighting obesity partnered with Medtronic, a prominent player in healthcare technology, to expand the reach of Allurion's AI-driven weight loss program. This expansion comes through a sales agency agreement targeting the Central and Eastern Europe, Middle East, and Africa (CEMA) region.

The Allurion Program combines the Allurion Balloon , the world's one of the first swallowable, procedure-free gastric balloon with the Allurion Virtual Care Suite. The suite is a remote patient monitoring solution, enhanced by the Allurion Iris AI Platform and the company's unique behavior change program. The Allurion Virtual Care Suite is also available to providers as a standalone product, allowing them to customize, monitor, and manage weight loss therapies for patients.The partnership enables Allurion to offer the Allurion Balloon and accelerate utilization of the Allurion Iris Artificial Intelligence (AI) Platform in the management of bariatric surgery patients by leveraging Medtronic channels during the collaboration. Such initiatives are projected to boost market growth.

Therefore, factors such as the rising prevalence of obesity, increasing technological advancements, and stratergic initiatives by key players are set to drive market growth during the forecast period.

Germany is Expected to Register a Significant Share of the Market Over the Forecast Period

The factors driving the growth of the patient monitoring devices market in Germany include the rising number of chronic diseases, the high prevalence of diabetes and obesity, and the increasing number of product launches.

Cancer is one of Germany's most prevalent chronic diseases, affecting thousands of Germans yearly. For instance, according to the data published by the World Cancer Research Fund (WCRF), there were 62.02 thousand new cases of lung cancer in 2022, out of which 36.87 thousand were in men and 22.15 thousand in women. The high number of cancer cases creates a demand for continuous health monitoring solutions. Cancer treatment often involves complex and prolonged therapies, such as chemotherapy and radiation, which require close monitoring of vital signs, symptoms, and treatment responses. Patient monitoring devices, including wearable sensors, remote monitoring systems, and telehealth platforms, enable real-time tracking of patient health, thereby driving market growth in the country.

Additionally, according to the data updated by the Catalan Institute of Oncology/International Agency for Research on Cancer (ICO/IARC) Information Centre on HPV and Cancer in March 2023, an estimated 4.66 thousand cervical cancer cases are diagnosed in Germany every year, and about 3.2% of women in the general population of Germany are estimated to harbor cervical human papillomavirus (HPV)-16/18 infection at a given time, and 76.5% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the high prevalence of HPV and its related cancers in the country is also expected to enhance the market growth.

Furthermore, the high prevalence of diabetes in the country is set to drive the market growth during the forecast period. For instance, according to the data published by the German Federal Government Agency in March 2024, around 34.6 thousand children and adolescents in Germany had type 1 diabetes in 2022.The prevalence increases with age and is highest among 14- to 17-year-olds. Thus, the high prevalence of diabetes in the country is projected to drive the demand for glucose-monitoring devices during the forecast period.

Moreover, the increasing number of product launches by the prominent players in the country is also set to drive market growth during the forecast period. For instance, in September 2023, DexCom, Inc. launched its Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM), which is one of the first CGM to connect to the Omnipod 5 AID System in Germany, helping users to protect against high and low glucose levels.

Therefore, factors such as the rising number of chronic diseases and the surging number of product launches by prominent players in the country are projected to accelerate the segment growth during the forecast period.

Europe Patient Monitoring Devices Industry Overview

The Europe patient monitoring devices market is semi consolidated due to a few large companies dominating most of the market share, including Abbott Laboratories, Baxter International Inc., Boston Scientific Corporation, GE Healthcare, and Johnson & Johnson, among others. Constant innovations by the remote patient monitoring companies in leading to the introduction of new products and a diversified product portfolio of digital platforms are prominent and key factors contributing for the strong presence of the companies.

Europe Patient Monitoring Devices Market Leaders

Europe Patient Monitoring Devices Market News

• April 2024: Koninklijke Philips N.V. has teamed up with smartQare to combine its advanced solution, viQtor, with Philips' well-known clinical patient monitoring platforms. This partnership aims to bring the next generation of continuous patient monitoring, both inside and outside hospitals, starting in Europe.
• March 2024: RDS, a medical device start-up received the CE mark for its patented wearable solution, MultiSense, designed for continuous Remote Patient Monitoring. Achieving this class IIa medical device certification, in line with Regulation (EU) 2017/745, marks a significant regulatory milestone for the company.